SCHEMBL6999550

SCHEMBL6999550

C=CCOC(=O)Nc1cc(CO)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CSNK2A2 P19784 1/20 0.42
CSNK2A1 P68400 1/20 0.42
RECQL P46063 1/20 0.41
NR3C2 P08235 10/20 0.40
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39
TUBB6 Q9BUF5 1/20 0.39
TUBB2B Q9BVA1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6998916 0.81 MEN1 (0.46) MEN1KMT2ACSNK2A2CSNK2A1TUBB4A
SCHEMBL19035598 0.77 CHRNB2 (0.61) MEN1KMT2ACHRNB2CHRNB4CHRNA3
SCHEMBL6215755 0.76 CYP3A4 (0.45) MEN1KMT2ARECQLKDM4EHSD17B10
SCHEMBL29575346 0.75 IGF1R (0.48) RECQLNR3C2
SCHEMBL1940483 0.75 IGF1R (0.48) RECQLNR3C2
SCHEMBL5913167 0.75 NR3C2 (0.53) MEN1KMT2ARECQLNR3C2
SCHEMBL2464156 0.74 MEN1 (0.49) MEN1KMT2ACSNK2A2CSNK2A1RECQL
SCHEMBL17919172 0.74 MEN1 (0.49) MEN1KMT2ACSNK2A2CSNK2A1TUBB4A
SCHEMBL501285 0.73 L3MBTL1 (0.52) RECQLNR3C2TYK2
SCHEMBL29507273 0.73 L3MBTL1 (0.52) RECQLNR3C2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6531466-B2 E.g., a 1-aza-10-(1-hydroxyethyl-11-oxo-4-(het-methylene)-tricyclo(7.2 .0.0(3,8))undec-2-ene-2-carboxylate; good activity against grampositive bacteria such as methicillin-resistant Staphylococcus aureus and epidermidis GLAXOSMITHKLINE SPA (IT) 2003-03-11 US disclosed
EP-0937078-B1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXOSMITHKLINE SPA (IT) 2003-02-12 EP disclosed
US-20010047094-A1 Tricyclic carbapenem compounds GLAXO WELLCOME SPA 2001-11-29 US disclosed
EP-0937078-A1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXO WELLCOME S.p.A. (IT) 1999-08-25 EP disclosed
WO-1998021210-A1 TRICYCLIC CARBAPENEM COMPOUNDS GLAXO WELLCOME S.P.A. (IT) 1998-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047094-A1 Tricyclic carbapenem compounds OXA1L, GNE, MGAM MEN1 2910/4885KMT2A 1665/4885CSNK2A2 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.